Sugi Predict

Sugi Predict / Compounds / SCHEMBL21069488

SCHEMBL21069488

SCHEMBL21069488

Cn1c(=O)[nH]c2ccc(N3CCN(C(=O)OC(C)(C)C)CC3)cc21

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ PDK2 Q15119 1/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ GPR119 Q8TDV5 8/20 0.45
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ NAMPT P43490 1/20 0.44
▸ DDB1 Q16531 1/20 0.44
▸ CRBN Q96SW2 1/20 0.44
▸ TSHR P16473 1/20 0.42
▸ ALK Q9UM73 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27166330 0.90 GPR119 (0.50) MAPTPDK2GPR119
SCHEMBL26923522 0.83 LMNA (0.42) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL26206220 0.83 HTR1A (0.42) ALDH1A1MEN1KMT2A
SCHEMBL30258792 0.82 PDE3B (0.43) MAPTPDK2GPR119
SCHEMBL30289116 0.81 NR1H2 (0.50) —
SCHEMBL24269312 0.81 TBK1 (0.46) —
SCHEMBL16270619 0.81 MAPT (0.54) MAPTLMNAALDH1A1PDK2SMN1; SMN2
SCHEMBL22502517 0.81 HTR7 (0.41) SMN1; SMN2
SCHEMBL22724875 0.81 ALDH1A1 (0.48) MAPTLMNAALDH1A1PDK2SMN1; SMN2
SCHEMBL23540833 0.80 KDM4E (0.51) MAPTGPR119HTTNAMPTDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 — — EP disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
EP-4626555-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF Tiger Biotherapeutics Inc. (US) 2025-10-08 — — EP disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
WO-2024155112-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS UPPTHERA, INC. (KR) 2024-07-25 — — WO disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 MAPT 1017/4885LMNA 2978/4885ALDH1A1 959/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 MAPT 1017/4885LMNA 2978/4885ALDH1A1 959/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885LMNA 1656/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.